Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

A legfontosabb adatok

Ki végzi
Thomas Jefferson University
Hol
Philadelphia (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
6 fő vett részt
Kezdés
2022. nov. 16.
Befejezés
2025. okt. 24.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • MRI-guided Intensity-Modulated Radiation Therapy
  • Antiandrogen Therapy
  • PSMA PET Scan
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Bone Scan
  • Biospecimen Collection
  • Quality-of-Life Assessment
A regiszteradat frissítve
2026. március 3.
Miért állt le
Loss of required MRI resources needed to conduct protocol-specified procedures

Ki vehet részt

Életkor
18 év felett
Nem
Csak férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Age: above 18 years
  • Participants must be histologically proven, adenocarcinoma prostate
  • Localized to the prostate without positive pelvic lymph node involvement
  • No distant metastatic disease assessed by pretreatment PSMA PET or bone scan and CT scan
  • High risk prostate cancer as defined by National Comprehensive Cancer Network (NCCN): Gleason score of 8- 10, clinical stage T3a or higher, or prostate specific antigen (PSA) > 20 ng/mL
  • Ability to receive long term hormone therapy
  • Karnofsky performance score (KPS) > 70
  • No prior history of therapeutic irradiation to pelvis
  • Patient willing and reliable for follow-up and quality of life (QOL)
  • English speaking/reading

Ki nem vehet részt

  • Previous radiation therapy (RT) to prostate or prostatectomy
  • A previous trans-urethral resection of the prostate (TURP)
  • Severe urinary symptoms or with severe International Prostate Symptom Score (IPSS) score despite being on hormonal therapy for 6 months which in the opinion of the physician precludes RT
  • Any contraindication to radiotherapy such as inflammatory bowel disease
  • Life expectancy < 2 years
  • Evidence of distant or pelvic metastasis at any time since presentation
  • Patients with known obstructive symptoms with stricture

Helyszínek itt: Egyesült Államok

  • Sidney Kimmel Cancer Center at Thomas Jefferson UniversityPhiladelphia, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This phase II trial tests whether magnetic resonance imaging (MRI)-guided hypofractionated radiation therapy works to reduce treatment time and side effects in patients with high risk prostate cancer. MRI-guided hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time directly to diseased tissue, reducing damage to healthy tissue. Using MRI-guided radiation therapy on areas of the prostate and pelvic lymph nodes may shorten overall treatment time compared to the longer standard of care therapy and may reduce the number and/or duration of side effects.

A vizsgálat csoportja

  • Treatment (MRI-guided IMRT, ADT)A vizsgált kezelés

    Patients undergo MRI-guided IMRT on study and receive SOC ADT throughout the trial. Patients may also undergo PSMA PET, CT, MRI, and bone scans at screening and undergo collection of blood samples throughout the trial.

    Kezelés: MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, Biospecimen Collection és Quality-of-Life Assessment

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase 2 Study of Extreme Hypofractionation Including Pelvic Nodes for High Risk Prostate Cancer Using MgRT (MRI Guided Radiation Therapy)
A regiszteradat frissítve
2026. március 3.